Menu

The AV 2025 HEALTHTECH APEX 20

20 Portfolio Companies We are Proud to Spotlight

Apex 50
Written by

Alumni Ventures

Published on

Read

5 min

We are pleased to announce our 2025 Healthtech Apex 20. This selection of ventures from AV’s portfolio of over 250 healthtech companies represents 20 of the names we’re excited to spotlight. These companies were chosen for their variety, innovative impact, performance, and upside. As one of the most active venture capital firms globally, Alumni Ventures routinely co-invests alongside brand-name lead VCs as we strive to be the industry’s “co-investor of choice.” Please explore our list of amazing healthtech portfolio companies.

The AV 2025 HEALTHTECH APEX 20

Oura

Captures and optimizes personalized biometric data

  • Partners with brands such as NBA, Equinox

Co-investor: Gradient Ventures

Pendulum

Microbiome therapies for metabolic diseases

  • Targeted formulations of natural bacterial strains help to rebalance the microbiome to restores and improve health

Co-investor: Sequoia Capital

Honor

Software to improve in-home senior care

  • Exceptional revenue growth
  • Proven management team

Co-investor: Andreessen Horowitz

Ezra

AI-Powered Cancer Screening

  • Launching the world’s first 30-min full body MRI scan

Co-investor: FirstMark

Forta Health

Family-powered autism support

  • Transforming adolescent and family mental health care
  • Contracted with seven of the top 10 largest U.S. health insurers

Co-investor: Insight Partners

Start Investing in Startups Like the Healthtech Apex 20

Precision

Developer of AI-powered brain-computer interfaces

  • Validated in large-animal studies
  • In-human trial approval expected in 2025

Co-investor: B Capital

Clarium

A New Era for Hospital Supply Chains

  • Modernizing healthcare demand planning

Co-investor: General Catalyst

The Helper Bees

Tech-Powered Senior Care

  • In-home care and support services for older adults

Co-investor: Northwestern Mutual

Start Investing in Startups Like the Healthtech Apex 20

Cambrian

Longevity Therapeutics

  • Discovery model that allows for a diversified approach to addressing age-related diseases
  • Exceptional team led by proven biotech innovators, strong early traction, and a large market opportunity

Co-investor: Anthos Capital

CapitalRx

Pharmacy Benefits Management

  • providing transparent, cost-effective solutions for prescription drug management
  • Streamlines processes and delivers personalized solutions to employers, health plans, and other organizations

Co-investor: General Catalyst

Unlearn

Leveraging AI to accelerate drug development

  • Creates “digital twins” — virtual patients that can simulate treatment responses and predict clinical outcomes
  • Used for research into Alzheimer’s, ALS, and more

Co-investor: 8VC, DCVC

RapidSOS

Tech company enhancing emergency response

  • Provides real-time, data-driven insights to first responders
  • Integrates data from devices and sensors to deliver actionable information

Co-investor: BlackRock

 Verge Genomics

AI for Drug Discovery

  • Accelerate the development of therapies for neurodegenerative diseases
  • Able to rapidly pinpoint potential therapeutic candidates

Co-investor: BlackRock

Start Investing in Startups Like the Healthtech Apex 20

Surge

Groundbreaking drug delivery platform

  • Partnerships across leading oncology centers
  • Enables precise targeting of solid tumors, using localized drug release to minimize side effects and maximize efficacy

Co-investor: Khosla Ventures

Anomaly

AI-Powered Healthcare Payment Combines

  • AI-driven platform, streamlining claims review and eliminating inefficiencies in payment processing
  • Delivering proven ROI for industry leaders

Co-investor: Khosla Ventures

Bionaut

Micro-Robotic Drug Delivery Systems

  • Central Nervous System drug delivery, addressing brain cancers and neurodegenerative diseases
  • Successful animal trials; upcoming human studies

Co-investor: Khosla Ventures

SonderMind

Mental health access through AI-driven tools

  • Scaling rapidly while delivering innovative mental health solutions
  • $77B+ market size

Co-investor: General Catalyst

Iambic

AI-driven biotech and drug design

  • Address complex drug design challenges
  • Platform has outperformed Google’s AlphaFold

Co-investor: Sequoia Capital

SHINE Technologies

Revolutionizing medical isotope production

  • Generating critical materials for cancer treatment and medical imaging
  • Roadmap transitions from medical isotopes to nuclear waste transmutation, then fusion power generation
  • Already producing 100,000 doses annually of cancer-fighting lutetium-177

Co-investor: Oaktree Capital

Ellipsis Health

AI-Based Health Diagnostics

  • AI system to detect biomarkers of mental health disorders from normal conversation
  • Implemented in United Health, HighMark Health, and HCA Healthcare

Co-investor: Khosla Ventures

Start Investing in Startups Like the Healthtech Apex 20

Download The 2025 Healthtech Apex 20 to explore the full list of ventures and learn more about their groundbreaking work.

America’s Largest VC Firm for Individual Investors

No representation is intended that any investment or outcome shown is or would be representative of any AV fund or the outcomes experienced by any AV investor.  The Apex 50 portfolio companies are provided for illustrative purposes only, and are not available to future investors except potentially in the case of follow-on investment.  Venture capital investing involves substantial risk, including risk of loss of all capital invested.  This communication is neither an offer to sell, nor a solicitation of an offer to purchase, any security.  Such offers are made only pursuant to the formal offering documents for the fund, which describe the risks, terms, and other information that must be carefully considered before an investment is made.

Written by

Alumni Ventures

Alumni Ventures is a network-powered VC firm that helps accredited individuals invest in venture capital.

LinkedIn
Twitter
Facebook
Tagged with

Follow us

AV Headquarters
670 N. Commercial Street
Suite 403
Manchester, NH 03101
General inquiries: [email protected]

Press inquiries: [email protected]

603-518-8112

Follow us

Neither Alumni Ventures nor any of its funds are sponsored by, affiliated with, or otherwise endorsed by any university. For further details see our Legal & Privacy Policy.

Video Policy: By consuming this content I acknowledge that I may be considering an investment with AV funds for my own or my client’s account. I agree that information contained herein may not be relied upon or used for any other purpose. Offers to purchase securities are only made through formal offering documents, which describe risks (which are significant), terms, and other important information that must be considered before an investment decision is made. To see Important Disclosure Information, visit: https://av-funds.com/disclosures.

Testimonial/Endorsement Policy: Testimonials/Endorsements were provided by the participants without compensation, but each participant has a relationship with Alumni Ventures (AV) from which they benefit. All views expressed are the individual’s own and do not represent the experience of all AV fund investors or companies in which AV funds invest. Please note that testimonials are no guarantee of future performance or success. Any provider of an endorsement that is affiliated with a portfolio company Alumni Ventures has received investment funding from AV, and may in the future seek and/or receive additional funding from AV. This circumstance constitutes a conflict of interest. Providers of testimonials or endorsements were not chosen at random or according to any objective basis, but rather on the basis of their relationship with AV.

Investor Portal Update Policy: Investor portfolio data is updated once per quarter in the AV Investor Portal.

Alumni Ventures is America’s largest VC firm for individual investors based on the combination of total capital raised, number of investments, and number of investors of leading VC firms as reported by Pitchbook and other publicly available information reviewed by AV.

(1) Internal Rate of Return (IRR) for AV Funds is net of management fees and incentive allocations applied to amounts distributed to investors, and gross of incentive allocations applicable to unrealized gains on investments held by AV Funds. IRR for AV Funds includes uninvested cash, unrealized investments, and amounts distributed to investors. The IRR shown for the Russell 2000 indices are gross of fees because indices are not managed investments, and it is not possible to invest directly in an index. For additional information see av-funds.com/disclosures. All investment involves risk, including risk of loss. Past performance is not necessarily indicative of future results. For more information on AV Funds’ investment returns, please see here.

Not an offer to sell, or a solicitation of an offer to purchase, any security. Such offers are only made pursuant to the formal offering documents for the fund, that describe the risks (which are significant), terms, and other important information that must be considered before an investment decision is made.
To see additional risk factors and investment considerations, visit: https://av-funds.com/disclosures.

Please click here to view additional investor policies.

© 2025, Alumni Ventures. All rights reserved.